EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities

Andrew N Gorobchenko, Karina T Umbetova, Abdigaffor Gadaev, Nargiza Mahkamova, Nasiba Sabirova, Aziz Kubaev

Cancer Chemotherapy and Pharmacology · 18.11.2026 · 96 (1)

DOI: 10.1007/s00280-026-04979-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 18.11.2026. Verfasst von Andrew N Gorobchenko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman I.M,. Sechenov First Moscow State Medical University of the Ru…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms, Cell- and Tissue-Based Therapy. Die Arbeit nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-engineered cell therapy has transformed the therapeutic landscape of certain blood cancers; however, extending it to new disease settings has not yet succeeded. Among several well-recognized barriers to broader success, including antigen heterogeneity and escape, limited trafficking to tumor sites, poor in vivo persistence, and the immunosuppressive tumor microenvironment, fratricide represents an additional important challenge. This phenomenon arises when the CAR target antigen is also naturally expressed on CAR-engineered cells or induced during cell activation, leading to unintended recognition and destruction of the therapeutic cells by their counterparts. It can also arise through less direct pathways, such as trogocytosis- or extracellular vesicle (EV)-mediated antigen transfer, which can make CAR-engineered cells vulnerable to fratricide because they do not naturally express the target antigen. Biologically, fratricide is a very significant mechanism that can impair cell expansion during manufacturing, reduce product yield and fitness, promote exhaustion, and compromise persistence after infusion. This review examines the biological basis of both target-intrinsic and acquired-antigen fratricide across CAR-engineered cell therapies. We comprehensively discuss current strategies to prevent fratricide, including antigen knockout or knockdown, intracellular protein retention, transient pharmacologic suppression of CAR signaling, selective enrichment of antigen-negative cells, inhibition of trogocytosis or EV pathways, and alternative receptor designs such as inhibitory, bispecific, and tandem CARs. We also review clinical advances in fratricide-resistant CAR-T cells and summarize related clinical trials. Finally, we consider an emerging counterpoint: under controlled conditions, fratricide may be deliberately exploited to enrich desirable cell populations. Mechanistic understanding of fratricide and its preventive strategies can help to develop safer and more efficacious CAR-engineered cellular therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsCell- and Tissue-Based TherapyHumansAnimalsTumor MicroenvironmentCell Engineering

Stichwörter der Autor:innen

CAR-NKCAR-TChimeric antigen receptorFratricideTrogocytosis

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman I.M,. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia.
  • Department of Internal Medicine in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan. abdigaf.gadaev@tma.uz.
  • Republican Specialized Scientific and Practical Medical Center of Cardiology, Tashkent, Uzbekistan.
  • Bukhara State Pedagogical Institute, Bukhara, Uzbekistan.
  • Department of Maxillofacial Surgery, Samarkand State Medical University, Samarkand, Uzbekistan.

Zitieren

APA

Gorobchenko, A. N., Umbetova, K. T., Gadaev, A., Mahkamova, N., Sabirova, N., & Kubaev, A. (2026). Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04979-6

Vancouver

Gorobchenko AN, Umbetova KT, Gadaev A, Mahkamova N, Sabirova N, Kubaev A. Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04979-6

BibTeX
@article{Gorobchenko2026,
  author = {Gorobchenko, Andrew N and Umbetova, Karina T and Gadaev, Abdigaffor and Mahkamova, Nargiza and Sabirova, Nasiba and Kubaev, Aziz},
  title = {Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04979-6}
}
Kostenlos starten →